RESOLVE-AF: Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy.
A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 400 participants.
Also called NCT05883631
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 400 participants
- Sponsor
- Cortex
- Registry
-
NCT05883631
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Belgium, Czechia, Netherlands
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT05883631. Non-randomized; no masking; primary purpose treatment. Start 2023-10-23 (actual); primary completion 2026-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- RESOLVE-AF: Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy.
- Acronym
- RESOLVE-AF
- Condition
- Atrial Fibrillation
- Condition
- Atrial Fibrillation, Persistent
- Condition
- Atrial Fibrillation Paroxysmal
- Condition
- Arrhythmia
- Condition
- Arrhythmias, Cardiac
- Condition
- Atrial Flutter
- Condition
- Atrial Fibrillation, Paroxysmal or Persistent
- Condition
- Atrial Arrhythmia
- Condition
- Atrial Tachycardia
- Intervention (Device)
- Electrographic Flow (EGF) mapping and ablation of EGF-identified sources of Atrial Fibrillation
- Intervention (Device)
- Electrographic Flow (EGF) mapping (no ablation)
- Lead sponsor
- Cortex
- Collaborator
- Ablacon, Inc.
Record details
- Record id
cardio:ct-nct05883631- Content hash
c6380add148132a66ed347906af846f831b9c18bfd32f4f742c800d8a602c011